Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies. The FDA announced it will hold meetings on July 23 and 24 with its Pharmacy Compounding Advisory Committee to discuss whether multiple peptide-related bulk drug substances should be considered for possible inclusion on the 503A bulks list.
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
Hims & Hers surges 4% as peptide policy shift unlocks growth
Shares of Hims & Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stock rose about 4% to $25.28 on Thursday morning after closing up 14% on Wednesday, as investors reacted to comments from Robert F.
Hims & Hers Stock Stays Hot Amid Peptides Buzz
Hims & Hers Health Inc (NYSE:HIMS) is one of the best performing stocks on the New York Stock Exchange (NYSE) today, up 4.5% to trade at $25.52.
FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade)
Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded peptides, unlocking renewed growth and reversing the current revenue multiple discount for HIMS. Conversely, stricter FDA action could eliminate a key growth driver, reinforcing HIMS' high-beta exposure to regulatory risk.
Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides
Hims & Hers Health's plan to enter the business of selling peptides is looking a lot more realistic.
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08% move from the preceding trading day.
Hims & Hers Advances a Consumer-Centric Digital Health Platform
HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
